Handbook of Incretin-based Therapies in Type 2 Diabetes

Buch | Softcover

IX, 92 Seiten

2016 | 1st ed. 2016
Springer International Publishing (Verlag)
978-3-319-08981-2 (ISBN)

Artikel merken

This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An ideal resource for medical professionals that treat patients with type 2 diabetes in hospital and clinical settings.

Stephen Gough is Professor of Diabetes at the University of Oxford and Consultant Physician at the Oxford University Hospitals NHS Trust. Professor Gough graduated in medicine from Leeds University Medical School, where he was later awarded a higher degree Doctorate in Medicine, which focused on cardiac dysfunction and abnormalities in coagulation and fibrinolysis present at the time of diagnosis of type 2 diabetes. He is currently based at the Oxford Centre for Diabetes, Endocrinology and Metabolism, where he is a practicing clinician in diabetes. His research interests and ongoing research studies include translational aspects of diabetes, with a focus on the physiology of islet cell and whole organ pancreas transplantation, incretin biology, and incretin therapies in diabetes. Professor Gough has previously had a strong interest in the genetic susceptibility to autoimmunity and this work has been extended into his work on pancreas transplantation. He has published his research extensively in peer-reviewed journals and has contributed to many national and international conferences and books on diabetes. In recent years, Professor Gough has helped develop translation research in diabetes in Oxford through a number of local and national initiatives, including the Oxford Biomedical Research Centre, and he is Clinical Lead in Diabetes for the Oxford Academic Health Science Network and the Oxford Local Clinical Research Network.

Introduction and disease overview.- Incretin hormones as a target for therapy.- Glucagon-like peptide receptor agonists.- Dipeptidyl peptidase-4 inhibitors.- Global position and recommendations for use.- Future and emerging therapies.

Erscheint lt. Verlag	17.6.2016
Zusatzinfo	IX, 92 p. 20 illus., 16 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	127 x 203 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Diabetologie
Schlagworte	Alogliptin • Diabetes • Dipeptidyl peptidase-4 inhibitor • DPP-4 inhibitor • Dulaglutide • Exenatide • Gliptins • GLP-1 analogue • Glucagon-like peptide-1 agonist • Incretin • Incretin mimetics • Incretin therapy • Linagliptin • Liraglutide • Lixisenatide • Oral antidiabetics • Oral hypoglycemics • Saxagliptin • Sitagliptin • type 2 diabetes • Vildagliptin
ISBN-10	3-319-08981-1 / 3319089811
ISBN-13	978-3-319-08981-2 / 9783319089812
Zustand	Neuware